Equities analysts expect OvaScience Inc (NASDAQ:OVAS) to report earnings per share of ($0.29) for the current quarter, Zacks reports. Three analysts have provided estimates for OvaScience’s earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.32). OvaScience posted earnings per share of ($0.64) during the same quarter last year, which would suggest a positive year over year growth rate of 54.7%. The company is scheduled to issue its next quarterly earnings report on Thursday, March 1st.
On average, analysts expect that OvaScience will report full-year earnings of ($1.48) per share for the current financial year, with EPS estimates ranging from ($1.51) to ($1.47). For the next year, analysts forecast that the firm will post earnings of ($1.11) per share, with EPS estimates ranging from ($1.33) to ($0.92). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for OvaScience.
OvaScience (NASDAQ:OVAS) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.15. OvaScience had a negative return on equity of 68.71% and a negative net margin of 20,090.13%.
Shares of OvaScience (NASDAQ OVAS) traded up $0.01 during trading hours on Tuesday, hitting $1.10. The stock had a trading volume of 275,320 shares, compared to its average volume of 1,202,200. OvaScience has a twelve month low of $1.07 and a twelve month high of $2.05. The stock has a market capitalization of $39.28, a P/E ratio of -0.60 and a beta of 3.73.
Several large investors have recently modified their holdings of the company. GMT Capital Corp purchased a new stake in shares of OvaScience in the third quarter valued at $1,138,000. Sabby Management LLC increased its stake in OvaScience by 20.2% in the second quarter. Sabby Management LLC now owns 509,300 shares of the biotechnology company’s stock valued at $795,000 after purchasing an additional 85,525 shares during the last quarter. Broadfin Capital LLC acquired a new position in OvaScience in the second quarter valued at $429,000. Susquehanna International Group LLP increased its stake in OvaScience by 87.2% in the second quarter. Susquehanna International Group LLP now owns 112,781 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 52,538 shares during the last quarter. Finally, Zacks Investment Management acquired a new position in OvaScience in the second quarter valued at $140,000. Institutional investors and hedge funds own 55.06% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/23/brokerages-expect-ovascience-inc-ovas-to-post-0-29-earnings-per-share.html.
OvaScience Company Profile
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.